Physician profile
Jonathan E Becker
NPI 1487897146
$5,782.59
in general payments reported to CMS, 2019-2025
22 companies · $1,670 in 2025
The $1,670 reported for 2025 was more than what 87% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $346 · 2022: $827 · 2023: $1,332 · 2024: $1,608 · 2025: $1,670.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,598 · Education: $12.01.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,597.68 |
| Education | $12.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $972.25 | 2022-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $811.71 | 2021-2025 | Spravato |
| Alkermes, INC. | $713.49 | 2021-2025 | Lybalvi, Aristada |
| Axsome Therapeutics, INC. | $695.35 | 2022-2025 | Auvelity, Sunosi |
| Abbvie INC. | $663.84 | 2022-2025 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $349.59 | 2023-2025 | Rexulti |
| Livanova USA, INC. | $310.91 | 2022-2023 | Vns Therapy Symmetry Model 8103 Generator |
| Neurocrine Biosciences, INC. | $203.87 | 2022-2024 | Ingrezza |
| Vanda Pharmaceuticals INC. | $176.64 | 2021-2025 | Fanapt, Hetlioz |
| Lundbeck LLC | $155.73 | 2021-2024 | Rexulti |
| Noven Therapeutics, LLC | $149.33 | 2024-2025 | Xelstrym, Secuado |
| E.R. Squibb & Sons, L.L.C. | $128.79 | 2024-2025 | Cobenfy |
| Idorsia Pharmaceuticals US INC | $117.91 | 2022-2025 | Quviviq, Quviviq |
| Jazz Pharmaceuticals INC. | $60.31 | 2021-2022 | |
| Tempus Ai, INC | $58.86 | 2024 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $50.83 | 2021-2022 | |
| Bausch Health US, LLC | $45.98 | 2022-2023 | Aplenzin |
| Neos Therapeutics, LP | $36.48 | 2021 | |
| Supernus Pharmaceuticals, INC. | $22.62 | 2025 | Qelbree |
| Corium, LLC | $20.58 | 2025 | Azstarys |
| Teva Pharmaceuticals USA, INC. | $19.86 | 2024 | Austedo Xr |
| Brainsway USA INC | $17.66 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Becker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.